Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study

A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferry, Tristan, Conrad, Anne, Senneville, Eric, Roux, Sandrine, Dupieux-Chabert, Céline, Dinh, Aurélien, Lustig, Sébastien, Goutelle, Sylvain, Briot, Thomas, Pham, Truong-Thanh, Valour, Florent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320277/
https://www.ncbi.nlm.nih.gov/pubmed/34337099
http://dx.doi.org/10.1093/ofid/ofab351
_version_ 1783730619389313024
author Ferry, Tristan
Conrad, Anne
Senneville, Eric
Roux, Sandrine
Dupieux-Chabert, Céline
Dinh, Aurélien
Lustig, Sébastien
Goutelle, Sylvain
Briot, Thomas
Pham, Truong-Thanh
Valour, Florent
author_facet Ferry, Tristan
Conrad, Anne
Senneville, Eric
Roux, Sandrine
Dupieux-Chabert, Céline
Dinh, Aurélien
Lustig, Sébastien
Goutelle, Sylvain
Briot, Thomas
Pham, Truong-Thanh
Valour, Florent
author_sort Ferry, Tristan
collection PubMed
description A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration of treatment of 6 months. No patients developed a serious adverse event.
format Online
Article
Text
id pubmed-8320277
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83202772021-07-30 Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study Ferry, Tristan Conrad, Anne Senneville, Eric Roux, Sandrine Dupieux-Chabert, Céline Dinh, Aurélien Lustig, Sébastien Goutelle, Sylvain Briot, Thomas Pham, Truong-Thanh Valour, Florent Open Forum Infect Dis Brief Reports A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration of treatment of 6 months. No patients developed a serious adverse event. Oxford University Press 2021-07-02 /pmc/articles/PMC8320277/ /pubmed/34337099 http://dx.doi.org/10.1093/ofid/ofab351 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Reports
Ferry, Tristan
Conrad, Anne
Senneville, Eric
Roux, Sandrine
Dupieux-Chabert, Céline
Dinh, Aurélien
Lustig, Sébastien
Goutelle, Sylvain
Briot, Thomas
Pham, Truong-Thanh
Valour, Florent
Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study
title Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study
title_full Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study
title_fullStr Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study
title_full_unstemmed Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study
title_short Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study
title_sort safety of tedizolid as suppressive antimicrobial therapy for patients with complex implant-associated bone and joint infection due to multidrug-resistant gram-positive pathogens: results from the tedisat cohort study
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320277/
https://www.ncbi.nlm.nih.gov/pubmed/34337099
http://dx.doi.org/10.1093/ofid/ofab351
work_keys_str_mv AT ferrytristan safetyoftedizolidassuppressiveantimicrobialtherapyforpatientswithcompleximplantassociatedboneandjointinfectionduetomultidrugresistantgrampositivepathogensresultsfromthetedisatcohortstudy
AT conradanne safetyoftedizolidassuppressiveantimicrobialtherapyforpatientswithcompleximplantassociatedboneandjointinfectionduetomultidrugresistantgrampositivepathogensresultsfromthetedisatcohortstudy
AT sennevilleeric safetyoftedizolidassuppressiveantimicrobialtherapyforpatientswithcompleximplantassociatedboneandjointinfectionduetomultidrugresistantgrampositivepathogensresultsfromthetedisatcohortstudy
AT rouxsandrine safetyoftedizolidassuppressiveantimicrobialtherapyforpatientswithcompleximplantassociatedboneandjointinfectionduetomultidrugresistantgrampositivepathogensresultsfromthetedisatcohortstudy
AT dupieuxchabertceline safetyoftedizolidassuppressiveantimicrobialtherapyforpatientswithcompleximplantassociatedboneandjointinfectionduetomultidrugresistantgrampositivepathogensresultsfromthetedisatcohortstudy
AT dinhaurelien safetyoftedizolidassuppressiveantimicrobialtherapyforpatientswithcompleximplantassociatedboneandjointinfectionduetomultidrugresistantgrampositivepathogensresultsfromthetedisatcohortstudy
AT lustigsebastien safetyoftedizolidassuppressiveantimicrobialtherapyforpatientswithcompleximplantassociatedboneandjointinfectionduetomultidrugresistantgrampositivepathogensresultsfromthetedisatcohortstudy
AT goutellesylvain safetyoftedizolidassuppressiveantimicrobialtherapyforpatientswithcompleximplantassociatedboneandjointinfectionduetomultidrugresistantgrampositivepathogensresultsfromthetedisatcohortstudy
AT briotthomas safetyoftedizolidassuppressiveantimicrobialtherapyforpatientswithcompleximplantassociatedboneandjointinfectionduetomultidrugresistantgrampositivepathogensresultsfromthetedisatcohortstudy
AT phamtruongthanh safetyoftedizolidassuppressiveantimicrobialtherapyforpatientswithcompleximplantassociatedboneandjointinfectionduetomultidrugresistantgrampositivepathogensresultsfromthetedisatcohortstudy
AT valourflorent safetyoftedizolidassuppressiveantimicrobialtherapyforpatientswithcompleximplantassociatedboneandjointinfectionduetomultidrugresistantgrampositivepathogensresultsfromthetedisatcohortstudy

Ejemplares similares